Life Science Start-Ups: Tech Transfer Deals, March 2014
This article was originally published in Start Up
Executive Summary
Derived from Strategic Transactions, a fully searchable premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced January through February 2014.
You may also be interested in...
Lupin Ends 2018 On High, Strikes Large MALT1 Deal With AbbVie
AbbVie has in-licensed Lupin’s MALT1 (mucosa-associated lymphoid tissue lymphoma translocation protein 1) inhibitor program for over $900m in potential milestone payments, bringing Christmas cheer for the Indian firm. The deal terms for the preclinical asset are rather striking.
The Biopharma A List: Taking The Pulse Of Newco Creation
The market for new company creation in the biopharma sector remains healthy and poised to continue fostering the establishment of start-ups, based on a new In Vivo study of the strong initial investments that pharma and biotech companies receive.
Deals In Depth: May 2022
In the top May alliance by deal value, Amphista Therapeutics and Bristol Myers Squibb aim to discover and develop targeted small-molecule protein degraders by leveraging Amphista's proprietary Eclipsys platform. BMS gets exclusive global rights to resulting products. Amphista will receive a $30M upfront payment, up to $1.25B in performance-based milestone payments, payment for a limited expansion of the collaboration, as well as royalties on global net sales.